The global GLP‑1 weight‑loss drug market is on track to approach $100 billion by the end of the decade, currently dominated by pharmaceutical heavyweights Eli Lilly and Novo Nordisk. Sustained robust demand leaves ample room for new entrants, among which Viking Therapeutics (VKTX) stands out as one of the most‑watched contenders.
This clinical‑stage biotech firm is advancing its lead weight‑loss candidate VK2735 into Phase 3 trials. Two Phase 3 studies for the injectable formulation have completed enrollment: one for obesity patients and another for people living with obesity plus type 2 diabetes. Some trial participants could finish their 78‑week treatment cycle as early as spring 2027. Meanwhile, the company is gearing up to launch a Phase 3 program for its oral version of VK2735. Encouraging Phase 2 data positions Viking as a potential rival to industry giants in the years ahead. Analysts have set a $92 price target for the stock, which currently trades around $33.
VKTX share prices are highly sensitive to updates from its weight‑loss drug pipeline. Back in early 2024, positive Phase 2 results triggered a 121% single‑session surge, though the stock has gradually pulled back from those highs. Investors are awaiting near‑term catalysts. Beyond pivotal Phase 3 readouts, data from a maintenance‑dosing study expected in the third quarter may also lift shares. Favorable Phase 3 clinical results would be the critical driver for the stock to move toward the $92 analyst target.
Still, bright prospects come with considerable risks. Viking has no commercialized products and posted zero revenue for fiscal year 2025. Heavy spending on clinical trials led to a net loss of approximately $359.6 million. The biotech maintains solid liquidity with a current ratio of roughly 9.3 times and zero debt; ample cash provides runway for R&D, yet ongoing research burns substantial free cash flow.
Multiple hazards hang over its pipeline and business. Its drug candidates face risks of clinical‑trial failure or regulatory rejection. Without recurring operating revenue, Viking will need future capital raises that could trigger shareholder dilution. Core development technology is licensed under an agreement with Ligand Pharmaceuticals, and termination of that deal would severely damage operations. The firm also confronts pipeline competition from peers including Altimmune. Operating with a lean workforce of only 53 full‑time employees, its fate hinges heavily on clinical outcomes.
For investors, growth‑oriented market participants with high risk tolerance may consider this speculative biotech play. Risk‑averse investors, by contrast, are better served by established large‑pharma names with proven revenue streams.
